Evommune EVMN 深 滬
已收盤 08-07 16:00:00 美东时间
14.08
+0.700
+5.23%
華盛通- 最 高14.36
- 今 開13.70
- 成交量 37.40万股
- 最 低 13.70
- 昨 收 13.38
- 總市值 5.07亿
- 52周最高 33.20
- 市盈率 靜 --
- 換手率 1.04%
- 52周最低 10.47
- 委 比 -6.67%
- 總股本 3601.84万
- 歷史最高 33.20
- 量 比 0.52
- 振 幅 4.93%
- 歷史最低 10.47
- 每 手 1
- 風險率 4.80%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $29
RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $30 to $29.
08-08 03:21
HC Wainwright & Co. Reiterates Neutral on Evommune
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Evommune (NYSE:EVMN) with a Neutral.
08-03 18:16
美股大行评级 | Bernstein上调闪迪目标价从1700美元升至3000美元；大摩上调谷歌-A目标价从375美元升至415美元
今日重点评级关注：Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元；康托·菲茨杰拉德：维持BioCryst制药"超配"评级，目标价从27美元升至29美元
07-01 10:40
Morgan Stanley Maintains Overweight on Evommune, Lowers Price Target to $26
Morgan Stanley analyst Judah Frommer maintains Evommune (NYSE:EVMN) with a Overweight and lowers the price target from $55 to $26.
06-30 20:56
This AAR Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Baird analyst RJ Milligan downgraded Alpine Income Property Trust Inc (NYSE:PINE) from Outperform...
06-30 20:51
HC Wainwright & Co. Downgrades Evommune to Neutral
HC Wainwright & Co. analyst Mitchell S. Kapoor downgrades Evommune (NYSE:EVMN) from Buy to Neutral.
06-30 18:41
William Blair Downgrades Evommune to Market Perform
William Blair analyst Matt Phipps downgrades Evommune (NYSE:EVMN) from Outperform to Market Perform.
06-30 00:52
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Monday. Shares of Biohaven Ltd (NASDAQ:BHVN) fell sharply in pre-market trading. Biohaven announced enrollment of first patient in its pivotal Phase 3 trial of BHV-1300 for Graves’ disease. B of A Securi...
06-29 20:11
